EUVIMEDEUVIMED entdecken
Open Access

Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omalizumab: A Study of 61 Cases

Pelin Hızlı iD, Burak Gülcen iD, Fatma Arzu Kılıç iD

Medical Science Monitor · 15.10.2024 · 30

DOI: 10.12659/msm.945935 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Science Monitor, online erschienen am 15.10.2024. Verfasst von Pelin Hızlı und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Balikesir University, Balikesir, Turkey. Hauptthemen laut MEDLINE: Quality of Life, Omalizumab, Acupuncture Therapy, Chronic Urticaria. Die Arbeit wurde bisher 5-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Quality of LifeOmalizumabAcupuncture TherapyChronic UrticariaHumansFemaleMaleAdultMiddle AgedTreatment OutcomeUrticaria

Substanzen

Omalizumab

Autor:innen und Institutionen

  • Department of Dermatology, Faculty of Medicine, Balikesir University, Balikesir, Turkey.
  • Department of Anatomy, Faculty of Medicine, Balikesir University, Balikesir, Turkey.

ORCID-Profile: Pelin Hızlı, Burak Gülcen, Fatma Arzu Kılıç

Zitieren

APA

Hızlı, P., Gülcen, B., & Kılıç, F. A. (2024). Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omalizumab: A Study of 61 Cases. Medical Science Monitor, 30. https://doi.org/10.12659/msm.945935

Vancouver

Hızlı P, Gülcen B, Kılıç FA. Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omalizumab: A Study of 61 Cases. Medical Science Monitor. 2024;30. doi:10.12659/msm.945935

BibTeX
@article{Hzl2024,
  author = {Hızlı, Pelin and Gülcen, Burak and Kılıç, Fatma Arzu},
  title = {Acupuncture Enhances Quality of Life and Disease Control in Chronic Spontaneous Urticaria Patients on Omalizumab: A Study of 61 Cases},
  journal = {Medical Science Monitor},
  year = {2024},
  volume = {30},
  doi = {10.12659/msm.945935}
}
Kostenlos starten →